GoAI
Get started
ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

ADMA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.84

+$0.08 · +0.82%

Aug 21, 4:00 PM ET

ADMA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

81

Deep Value

Momentum

28

Weakening

Sentiment

68

Bullish

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Adam S. Grossman
Listed since
Oct 17, 2013
Employees
644

Market position

Day range

Current $9.84

52-week range

Current $9.84

Open
$9.77
Previous close
$9.76
Volume
1.48M
0.33× average
Average volume
4.45M
Average daily volume
Market cap
2.28B USD
Beta
0.77
Market reference 1
50-day average
$8.9435
+10.02% above average
200-day average
$12.9282
-23.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.34B USD
P/E (TTM)
13.67×
P/B (TTM)
5.5×
P/S (TTM)
4.45×
EV / EBITDA
21.93×
Earnings yield
3.38%
Free cash flow yield
0.64%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
64.71%
Operating margin
42.26%
Net margin
32.98%
Return on equity
30.78%
Return on assets
23.54%
Return on invested capital
27.57%

Financial health

Debt / equity
0.5×
Current ratio
6.71×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends72%14%-45%-103%Gross margin, FY2021: 1.45%Gross margin, FY2022: 22.89%Gross margin, FY2023: 34.44%Gross margin, FY2024: 51.48%Gross margin, FY2025: 57.39%Operating margin, FY2021: -72.12%Operating margin, FY2022: -25.55%Operating margin, FY2023: 8.38%Operating margin, FY2024: 32.59%Operating margin, FY2025: 37.53%Net margin, FY2021: -88.52%Net margin, FY2022: -42.77%Net margin, FY2023: -10.94%Net margin, FY2024: 46.35%Net margin, FY2025: 28.80%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 1.45%. Gross margin FY2022 22.89%. Gross margin FY2023 34.44%. Gross margin FY2024 51.48%. Gross margin FY2025 57.39%. Operating margin FY2021 -72.12%. Operating margin FY2022 -25.55%. Operating margin FY2023 8.38%. Operating margin FY2024 32.59%. Operating margin FY2025 37.53%. Net margin FY2021 -88.52%. Net margin FY2022 -42.77%. Net margin FY2023 -10.94%. Net margin FY2024 46.35%. Net margin FY2025 28.80%.

Income trends

Revenue

510.17M USD+19.63%

Operating income

191.44M USD+37.75%

Net income

146.93M USD-25.67%
Income trends across reported periods568.36M USD335.63M USD102.9M USD−129.83M USDRevenue, FY2021: 80.94M USDRevenue, FY2022: 154.08M USDRevenue, FY2023: 258.22M USDRevenue, FY2024: 426.45M USDRevenue, FY2025: 510.17M USDOperating income, FY2021: −58.37M USDOperating income, FY2022: −39.37M USDOperating income, FY2023: 21.63M USDOperating income, FY2024: 138.98M USDOperating income, FY2025: 191.44M USDNet income, FY2021: −71.65M USDNet income, FY2022: −65.9M USDNet income, FY2023: −28.24M USDNet income, FY2024: 197.67M USDNet income, FY2025: 146.93M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 80.94M USD. Revenue FY2022 154.08M USD. Revenue FY2023 258.22M USD. Revenue FY2024 426.45M USD. Revenue FY2025 510.17M USD. Operating income FY2021 −58.37M USD. Operating income FY2022 −39.37M USD. Operating income FY2023 21.63M USD. Operating income FY2024 138.98M USD. Operating income FY2025 191.44M USD. Net income FY2021 −71.65M USD. Net income FY2022 −65.9M USD. Net income FY2023 −28.24M USD. Net income FY2024 197.67M USD. Net income FY2025 146.93M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue510.17M USD426.45M USD258.22M USD154.08M USD80.94M USD
Cost of goods sold217.41M USD206.9M USD169.27M USD118.82M USD79.77M USD
Gross profit292.77M USD219.55M USD88.94M USD35.27M USD1.17M USD
Research and development4.76M USD1.81M USD3.3M USD3.61M USD3.65M USD
Selling, general, and administrative91.58M USD74.12M USD59.02M USD52.46M USD42.9M USD
Operating expenses101.32M USD80.57M USD67.31M USD74.63M USD59.55M USD
Interest income1.87M USD2.1M USD1.62M USD44.83K USD34.53K USD
Interest expense7.11M USD13.93M USD25.03M USD19.28M USD13.06M USD
Depreciation and amortization8.1M USD8.05M USD8.33M USD7.11M USD5.5M USD
Operating income191.44M USD138.98M USD21.63M USD−39.37M USD−58.37M USD
Net income146.93M USD197.67M USD−28.24M USD−65.9M USD−71.65M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$18.67

89.74% upside
Past 12 months12-month forecastHigh $21.00Average $18.67Low $17.00

ADMA news

gurufocus.com

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA PR Newswire

Read source
gurufocus.com

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law PR Newswire LOS

Read source
prnewswire.com

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the…

Read source
prnewswire.com

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the…

Read source
newsfilecorp.com

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain…

Read source
prnewswire.com

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ:…

Read source

ADMA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ADMA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Small-Cap ETF logoiShares Core S&P Small-Cap ETFIJR
Market value
131.63M
Weight
0.12%
AUM
111.19B USD
Expense ratio
0.06%
Price / 1D
$147.31+0.64%
First Trust NYSE Arca Biotechnology Index Fund logoFirst Trust NYSE Arca Biotechnology Index FundFBT
Market value
96.87M
Weight
3.33%
AUM
2.94B USD
Expense ratio
0.55%
Price / 1D
$271.07+1.10%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
79.61M
Weight
0.70%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
59.66M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
57.58M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
22.54M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
21.4M
Weight
0.01%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
State Street SPDR Portfolio S&P 600 Small Cap ETF logoState Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Market value
21.26M
Weight
0.12%
AUM
17.03B USD
Expense ratio
0.03%
Price / 1D
$57.28+0.61%

Continue in GoAI

Research ADMA

research.disclaimer